TARS 241115 60.00C (TARS241115C60000) Stock Options, News & Quotes

US OptionsDetailed Quotes

TARS241115C60000

Watchlist

1.00
-1.55-60.78%

15min DelayClose Nov 13 16:00 ET

2.00High0.90Low

Intraday

5D
Daily

News

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
GlobeNewswire16:05 ET
Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results
Jerry Kronenberg16:29 ET
Tarsus Pharmaceuticals Reports Q3 EPS (61c), Consensus (94c)
TipRanks16:26 ET
Tarsus Pharmaceuticals | 10-Q: Quarterly report
SEC16:18 ET · Announcements
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M
MT Newswires16:12 ET
Express News | Tarsus Pharmaceuticals Q3 Basic EPS USD -0.61
Reuters16:05 ET

Comments

Jerry Kronenberg

4 hours ago

Columns Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results

$Tarsus Pharmaceuticals (TARS.US)$ rose some 15% in after-hours trading Wednesday after the biotech reported a narrower-than-Q3 expected loss and better-than-forecast quarterly revenues.
TARS – which makes XDEMVY, a prescription eye drop to treat optical disease Demodex blepharitis – gained 14.5% to $53.25 shortly before 4:30 p.m. ET after unveiling a $0.61 Q3 loss, beating the $0.92 that analysts had reportedly f...

MMu

Oct 29 15:16

$Tarsus Pharmaceuticals (TARS.US)$ wonder which 2 pharmas are bidding for Tarsus!!

Stock_Drift

Oct 28 04:33

Pre Market Ticks. 5:32am 10/28

$Jet.AI (JTAI.US)$ $ProShares UltraShort Bloomberg Crude Oil ETF (SCO.US)$ $Phunware (PHUN.US)$ $ImmunityBio (IBRX.US)$ $Longeveron (LGVN.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Tarsus Pharmaceuticals (TARS.US)$ $XTL Biopharmaceuticals (XTLB.US)$ $LENZ Therapeutics (LENZ.US)$ $TC BioPharm (TCBP.US)$ $Top Wealth Group Holding (TWG.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies (PXDT.US)$
📊⚡️📊

Jaguar8

Aug 8 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results